Argentina will be able to produce Sputnik V in the country – telam

The Russian vaccine is based on an adenovirus, the same one used since 1953 to fight ballooning.

The Russian government has announced the official launch of the Sputnik V vaccine and confirmed that Argentina will be able to participate in the production locally, as confirmed by the Russian authorities during a presentation at the United Nations.

“Because it is completing its clinical trials with positive results and we are already starting to mass produce it, Sputnik V is currently one of the vaccines that leads the World Health Organization list of developments.” , said the Minister of Health. from Russia, Mikhail Murashko.

Putin orders ‘large-scale’ coronavirus vaccination to start in Russia next week

Participation of Argentina

But who confirmed Argentina’s participation in the production of the vaccine was the Managing Director of the Russian Direct Investment Fund (RDIF), Kirill Dmitriev, the company in charge of its development.

Dmitriev argued that Russia’s goal is to “generate a spirit of partnership and joint work, so that countries like India, China, Korea, Brazil and Argentina, among other things, they will be able to produce the vaccine on their territory. “

In addition, he ratified the efficiency of Sputnik V is 91.4 percent, and thise is the cheapest of those presented so far, costing less than $ 10 each of the two doses necessary to achieve efficiency.

Dmitriev also confirmed that the vaccine should be stored between 2 and 8 degrees, key information for the operation countries must deploy to immunize their populations.

Specialists make sure the vaccine is effective seven days after the second dose.

In the presentation, Dmitriev recalled that Sputnik V reaches its effectiveness 7 days after the second dose and 28 days after the first, but the percentage of 91.4% could reach 95% after 42 days.

He also recalled that the Russian vaccine is based on an adenovirus, the same one used since 1953 to fight Ebola, that more than 40 countries which “represent 40 percent of the world’s population have expressed interest” in Sputnik V and that 1,200 million doses have already been produced.

The advantages of local production

The possibility of participating in the production process will ensure Argentina to reduce costs and improve access to the vaccine.

The national government had announced that the agreement with Russia guaranteed the availability of 25 million doses of Sputnik V., to which will be added 22 million additional doses from the agreement with AstraZeneca, the vaccine developed with the University of Oxford, UK. United.

As Minister Mikhail Murashko explained in his presentation to the United Nations, “clinical trials, which involved over 45,000 people, have been successfully carried out in Russia, Belarus, India, Venezuela and the Emirates. United Arabs. For this reason, we are starting vaccination campaigns here and already more than 100,000 Russian citizens belonging to risk groups have been vaccinated “.

Regarding side effects, the Russian developers pointed out that “all vaccines contain them, because there is not one that is 100% safe. area of ​​application, headache and fever “.